3.58
+0.22(+6.55%)
Currency In USD
| Previous Close | 3.36 |
| Open | 3.4 |
| Day High | 3.75 |
| Day Low | 3.4 |
| 52-Week High | 5.39 |
| 52-Week Low | 0.83 |
| Volume | 795,979 |
| Average Volume | 701,589 |
| Market Cap | 222.02M |
| PE | -2.25 |
| EPS | -1.59 |
| Moving Average 50 Days | 2.01 |
| Moving Average 200 Days | 1.42 |
| Change | 0.22 |
If you invested $1000 in Pyxis Oncology, Inc. (PYXS) since IPO date, it would be worth $271.21 as of October 20, 2025 at a share price of $3.58. Whereas If you bought $1000 worth of Pyxis Oncology, Inc. (PYXS) shares 3 years ago, it would be worth $2,069.36 as of October 20, 2025 at a share price of $3.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
GlobeNewswire Inc.
Oct 09, 2025 11:30 AM GMT
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Seni
Pyxis Oncology to Participate in September Investor and Industry Conferences
GlobeNewswire Inc.
Aug 21, 2025 11:30 AM GMT
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Ch